Nuvo Pharmaceuticals™ Announces the Filing of the Business Acquisition Report Related to the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo

- March 15th, 2019

Nuvo Pharmaceuticals (TSX:NRI,OTCQB:NRIFF) has announced the filing of the business acquisition report on SEDAR related to an acquisition of a portfolio of more than 20 products and associated personnel and infrastructure to continue the products’ management and growth from Aralez Pharmaceuticals. As quoted in the press release: The BAR includes: Audited annual carve-out financial statements, … Continued

Nuvo Pharmaceuticals (TSX:NRI,OTCQB:NRIFF) has announced the filing of the business acquisition report on SEDAR related to an acquisition of a portfolio of more than 20 products and associated personnel and infrastructure to continue the products’ management and growth from Aralez Pharmaceuticals.

As quoted in the press release:

The BAR includes:

  1. Audited annual carve-out financial statements, the notes thereto and the auditor’s report thereon of the Aralez Canada business and the related assets acquired from Pozen Inc. pursuant to the Aralez Transaction (together, the Acquired Business), as at and for the years ended December 31, 2017 and 2016;
  2. Unaudited interim carve-out financial statements and the notes thereto of the Acquired Business as of and for the nine-month periods ended September 30, 2018 and 2017; and
  3. Unaudited pro forma combined financial statements and notes thereto of the Company that give effect to the Aralez Transaction and the Deerfield Financing, comprised of the pro forma combined statement of loss and comprehensive loss (including pro forma loss per share) for the twelve-month period ended December 31, 2017 and the pro forma combined statement of financial position as at September 30, 2018 and the pro forma combined statement of loss and comprehensive loss (including pro forma loss per share) for the nine-month period ended September 30, 2018.

A supplementary presentation summarizing select information contained in the BAR and highlighting the Company’s adoption of and reconciliation of certain non-IFRS financial measures including Adjusted Total Revenue and Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA) is posted on the Company’s website at www.nuvopharmaceuticals.com.

Click here to read the full press release.

Should you invest in the 2020 pharmaceutical market?

Read our FREE outlook report!
 

Leave a Reply